Delanzomib

• Description:

  Delanzomib (CEP-18770) is a potent and orally active chymotrypsin-like activity of the proteasome inhibitor with an IC50 of 3.8 nM. Delanzomib inhibits NF-κB activity, induces cancer cell apoptotic, and has strong antiangiogenic and anti-cancer activities[1].

• Product Name Alternative:

  CEP-18770

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H312, H332

• Target:

  Apoptosis; NF-κB; Proteasome

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Metabolic Enzyme/Protease; NF-κB

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Delanzomib.html

• Purity:

  98.0

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC(C)C[C@@H](B(O)O)NC([C@@H](NC(C1=NC(C2=CC=CC=C2)=CC=C1)=O)[C@H](O)C)=O

• Molecular Formula:

  C21H28BN3O5

• Molecular Weight:

  413.28

• Precautions:

  H302, H312, H332

• References & Citations:

  [1]Glinsukon T, et al. Acute toxicity of capsaicin in several animal species[J]. Toxicon, 1980, 18 (2) : 215-220.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  [847499-27-8]